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Plasminogen Activator Activity in Tears after Excimer
Laser Photorefractive Keratectomy
Adrienne Csutak,1,4 Jo´zsef To¨zse´r,2 La´szlo´ Be´ke´si,1 Ziad Hassan,1 Andra´s Berta,1
and David M. Silver3,4
PURPOSE. To quantify changes of plasminogen activator activity in tear fluid during corneal re-
epithelialization after excimer laser photorefractive keratectomy (PRK).
METHODS. Tear samples were collected with glass capillaries from 77 eyes of 42 patients immedi-
ately before and immediately after PRK treatment and on postoperative days 3 and 5. In 20 patients,
the contralateral eye was similarly sampled to serve as control. Plasminogen activator activity in the
tear samples was measured by a spectrophotometric method using human plasminogen and
chromogenic peptide substrate, D-valyl-L-leucyl-L-lysine-p-nitroanilide (S-2251).
RESULTS. In tears of all eyes that underwent PRK, the plasminogen activator activities were lower
immediately after PRK than were the preoperative values. For patient eyes with normal wound
healing, tear plasminogen activator activities were significantly elevated above the preoperative
level on the third postoperative day and then returned to the preoperative level by the fifth
postoperative day. In contrast, tear plasminogen activator activities remained low through the third
postoperative day in all (six) eyes in which haze developed after 3 to 6 months. The contralateral
control eyes showed no appreciable change in plasminogen activator activity over the 5-day period.
CONCLUSIONS. Plasminogen activator activity levels measured in tears of excimer laser PRK-treated
eyes may serve as a predictor of wound healing. Extended low levels of plasminogen activator
activity through the third postoperative day correlate with the development of corneal healing
abnormalities (haze). The low plasminogen activator activity could be not only an accompanying
sign but also a cause of defective corneal wound healing. (Invest Ophthalmol Vis Sci. 2000;41:
3743–3747)
Excimer laser photorefractive keratectomy (PRK) is usedfor the correction of myopia, hyperopia, and astigma-tism. The excimer laser removes tissue through photo-
ablative decomposition by delivering incident photon energy
that is sufficient to break molecular bonds. Selective removal of
tissue across the anterior surface results in a change in anterior
corneal curvature. In the majority of cases the refractive out-
come is within 60.5 D of that intended, although there is some
variation in the refractive outcome, depending on the preop-
erative refractive error. The surgical outcome may also be
influenced by individual variability in wound healing and phar-
macologic intervention.1
PRK complications include excessive myopic regression
and disturbances in corneal transparency (haze, scarring).2,3
Histologically, this is due to the presence of unstructured
collagen fibers excreted by activated keratocytes and affected
extracellular matrix. When present, haze usually appears in the
first month, its intensity being highest in the postoperative 3 to
6 months. In most cases it disappears later. Although complete
re-epithelialization usually occurs in human corneas at 2 to 4
days after surgery, normal epithelial thickness is not observed
until 6 months after surgery.4 Scarring is caused by activated
stromal keratocytes and inflammatory cells that invade the
stroma after re-epithelialization. The activated keratocytes se-
crete collagen fibers that have different structures from normal
collagen. As a result of this hyperplastic response, the thick-
ness of the stroma increases, the corneal refractive power
subsequently increases, and a myopic shift occurs. Regression
can be explained not only by the stromal hyperplastic reaction
but by epithelial hyperplasia as well.5,6
Wound healing is regulated by two major systems that are
controlled by activators and inhibitors. The first system is the
plasminogen activator–plasmin system, which is involved in
the degradation and removal of damaged extracellular ma-
trix.7,8 The second system is the activated keratocyte sys-
tem,8–13 which is involved in the replacement of damaged
collagen by synthesizing new collagen9–12 and the collagen
matrix of glycosaminoglycans.10–13 This process is very impor-
tant in epithelial regrowth, but by activating the synthetic
activity of keratocytes, it can cause scar formation. The ulcer-
ative mechanism with persistent epithelial defect14–16 is initi-
ated if plasminogen activator is released with increased or
prolonged activity.14,15
Normal corneal epithelial cells do not release plasminogen
activator, but damaged corneal epithelium causes keratocytes
From the Departments of 1Ophthalmology and 2Biochemistry and
Molecular Biology, University Medical School of Debrecen, Hungary;
the 3Applied Physics Laboratory, Johns Hopkins University, Laurel,
Maryland; and the 4Department of Ophthalmology, Wilmer Eye Insti-
tute, The Johns Hopkins Medical School, Baltimore, Maryland.
Supported in part by the US Department of the Navy, Naval Sea
Systems Command under Contract N00024-98-D-8124 at JHU/APL.
Submitted for publication December 27, 1999; revised June 16,
2000; accepted June 23, 2000.
Commercial relationships policy: N.
Corresponding author: David M. Silver, Applied Physics Labora-
tory, Johns Hopkins University, 11100 Johns Hopkins Road, Laurel, MD
20723-6099. david.m.silver@jhuapl.edu
Investigative Ophthalmology & Visual Science, November 2000, Vol. 41, No. 12
Copyright © Association for Research in Vision and Ophthalmology 3743
to release plasminogen activator, which converts plasminogen,
already present in the stroma, to plasmin. The plasmin in turn
feeds back to fibroblast cells, inducing them to secrete more
plasminogen activators; activates the latent procollagenases to
collagenases, which results in collagen molecule degradation;
and degrades the fibronectin in the extracellular matrix. In
addition, plasmin might stimulate the replication of endothelial
cells, promoting angiogenesis, which has been shown to be an
important factor in tissue repair.17 Plasmin might generate
chemotactic factors for polymorphonuclear neutrophils from
the complement system and cause the formation of vasoactive
kinins, which result in the increased entrance of serum anti-
proteases into the corneal stroma.14
Plasminogen activator plays a pivotal role in the plasmin-
ogen activator–plasmin wound-healing system. Plasminogen
activator is a normal component of tear fluid, whose concen-
tration is influenced by biochemical transformations in the
cornea. Thus, the progression of corneal wound healing may
be followed by determining the plasminogen activator levels in
the tear fluid.18 The purpose of this study was to quantify the
changes of plasminogen activator activity in tear fluid during
corneal re-epithelialization after excimer laser PRK.
MATERIALS AND METHODS
Forty-two patients (26 female, 16 male) who underwent PRK
surgery between the ages of 17 and 51 years (mean, 27 6 9
[SD] years), were selected for this study after obtaining in-
formed consent in adherence to the Declaration of Helsinki.
For a given patient, the PRK was performed one eye at a time
with an interval of 1 to 2 weeks between surgeries. Both PRK
eyes were sampled except for seven patients (three female,
four male), who volunteered for sampling from only one eye.
Excluded from consideration were patients from whom a 15-ml
tear sample could not be obtained within 3 minutes. For 20 of
the surgeries for which additional informed consent could be
obtained, the contralateral eye was sampled as a control eye.
This provided a sample population of 77 eyes (41 right, 36 left)
and 20 contralateral control eyes. Data are means 6 SD. Pre-
operative mean refractive error was 23.0 6 3.0 D (range, 5.0
to 210.0 D). Eighteen of the eyes had preoperative astigma-
tism (mean, 21.5 6 0.6 cylinder; range, 21.0 to 22.75 cylin-
der). Seventeen of the patients had previous usage of contact
lenses (mean usage, 4 6 2 years; range, 1–9 years).
PRK treatments with an excimer laser (Keratom II ArF;
Schwind, Kleinostheim, Germany; [193 nm]) were performed
by the same surgeon at Vital-Laser LLC, Department of Oph-
thalmology, University Medical School of Debrecen, Hungary.
De-epithelialization was performed with a blunt keratome
blade knife after epithelial marking with a 6.0- to 6.5-mm
Hoffer trephine for spherical correction and 7.5 to 8.0 mm for
astigmatic correction centered over the pupil. The epithelium
was scraped gently from periphery to center, with care taken
to avoid damaging the surface of Bowman‘s layer. Residual
epithelial debris was removed with a sterile microsponge.
Epithelial anesthesia was induced using 0.4% oxybuprocaine
hydrochloride eyedrops. The diameter of the ablation zone was
6.1 6 0.2 mm (range, 6.0–6.5 mm) for patients without astig-
matism. For those with astigmatism, the diameter of the astig-
matic ablation mask was 7.5 6 0.6 mm (range, 6.0–8.1 mm),
and the spherical ablation mask was 5.7 6 0.1 mm (range,
5.3–6.0 mm). The mean ablation depth of the PRK surgery was
48 6 22 mm (range, 12–120 mm). The mean ablation depth (47
mm) of the subgroup without astigmatism was not statistically
significantly different (P . 0.66) from the mean ablation depth
(50 mm) of the astigmatism subgroup.
The postoperative treatment included antibiotic eyedrops
(Ciloxan; Alcon, Fort Worth, TX), hourly on the first postop-
erative day and five times daily during the next 5 days for each
patient. The eyedrops were withdrawn for at least 8 hours
before tear sampling to avoid the possibility of tear sample
dilution. After the 5-day period, Flucon and Tears Naturale
(both from Alcon) were administered 5 times daily during the
first month, reduced to four times daily for the second month,
and to three times daily for the third month. No other treat-
ment was used during this period. All patients underwent
follow-up examinations at 1, 3, and 6 months after the PRK
procedure.
Tear samples for plasminogen activator analyses were ob-
tained immediately before and immediately after the PRK treat-
ment and on the third and fifth postoperative days from the
PRK-treated eye and the contralateral eye where it was used.
Samples consisted of tears collected with glass capillaries16,19
under slit lamp illumination from the lower tear meniscus (a
horizontal thickening of the precorneal tear film by the lower
margin) at the lateral canthus.16 Care was taken not to touch
the conjunctiva. We used the same collection method through-
out the study. The duration of the sampling time was recorded,
and the secretion rate was calculated in microliters per minute,
dividing the obtained tear volume by the time of sample col-
lection. Samples used in this investigation had secretion rates
of 5 to 15 ml/min for both the PRK eyes and the contralateral
controls. Samples were centrifuged (1800 rpm) for 8 to 10
minutes right after sample collection, and supernatants were
deep-frozen at 280°C and were thawed only once for measure-
ments.
Plasminogen activator activity was measured in the sample
tears by a spectrophotometric method using human plasmin-
ogen and a plasmin-specific chromogenic peptide substrate,
D-valyl-L-leucyl-L-lysine-p-nitroanilide (S-2251).20 This assay is
sensitive predominantly to urokinase-like plasminogen activa-
tor.16 Plasminogen and the S-2251 were purchased from Chro-
mogenix (Moˆlndal, Sweden). Urokinase standard was pur-
chased from Choay (Paris, France). This assay is suitable to
measure plasmin activity but can also be used for determining
plasminogen activator activity by adding plasminogen to the
reagents. Plasminogen activator activity was measured as de-
scribed by Shimada et al.20 with the following modifications
according to To¨zse´r et al.16 and To¨zse´r and Berta21: 5 ml tear,
or standard urokinase, or plasmin was incubated in 100 ml of
0.05 Tris buffer (pH 7.4) at 37°C in the presence of 0.5 mM
chromogenic substrate S-2251 and 1 mM human plasminogen
in wells of microtiter plates. After 4 hours’ incubation, the
reaction was terminated by the addition of 500 ml of 8 M acetic
acid. The absorption was measured at 405 nm with a spectro-
photometer (Multiscan MS; Labsystem, Helsinki, Finland). Plas-
minogen independent amidolytic activity was measured simi-
larly, but plasminogen was omitted from the incubation
mixture. The absorption difference between the values ob-
tained with and without plasminogen was considered to be
due to the plasminogen activator activity in tear, whereas the
absorbance value obtained without plasminogen was consid-
ered to be plasminogen-independent amidolytic activity. Based
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on the absorption values gained in the same system with
urokinase standard solutions with different concentrations we
produced a calibration curve. The plasminogen activator activ-
ities of the measured samples were calculated with this cali-
bration curve and were expressed in international units per
milliliter urokinase equivalent values. Plasminogen-indepen-
dent activity was found to be negligible in all the tear samples.
Determination of haze was made without any knowledge
of the plasminogen activator levels for any of the patients.
Therefore, there was no bias in the determination of haze or in
the correlation of plasminogen activator activity with haze. The
haze-grading system of Hanna was adopted.13
Standard statistical procedures were used to compare pa-
tient characteristics between different groups (t-test for means
of correlated pairs). Plasminogen activator activities were com-
pared between different groups using t-tests for means with
equal variances. Comparisons with control eyes were per-
formed using paired t-tests. Differences resulting in P , 0.05
were considered significant, and P , 0.001 was considered
highly significant.
RESULTS
During the 5-day period of tear sampling for each eye, there
were no clinical features that distinguished any of the eyes.
However, six of the PRK-treated eyes (five patients: four fe-
male, one male) showed mild to marked subepithelial corneal
haze (grade 1–2)13 between the third and sixth month, accom-
panied simultaneously by a slight decrease in visual acuity.
These six eyes were retrospectively labeled complicated cases
and represent an 8% (6/77) frequency of occurrence. The
remaining eyes did not exhibit visual complications and were
retrospectively designated normal cases. Three of the patients
had one complicated and one normal eye; one patient had two
complicated eyes; and one of the patients with a complicated
eye had volunteered only one eye for sampling.
Individual values of the plasminogen activator activities
for each eye of the normal and complicated groups are shown
in Figure 1. The plasminogen activator activities of the two
groups are distinctly separated on the third postoperative day
and overlap at the other three measurement times. Figure 2
shows the individual values of the plasminogen activator activ-
ities for all the contralateral eyes.
Patient characteristics are provided in Table 1, and visual
and surgical characteristics of the eyes are given in Table 2.
There are no statistically significant differences in age, length
of contact lens wear, prior refractive correction, or extent of
astigmatism between the two groups.
For the plasminogen activator measurements, the normal
cases established a pattern as tabulated in Table 3. There was
a decrease in the mean value of plasminogen activator to
approximately 11% of the preoperative mean level immediately
after the PRK treatment, an increase of 41% above the preop-
erative level by the third postoperative day, and a return to
within 4% of the preoperative level by the fifth postoperative
day. There was not a significant difference (P 5 0.15) between
the preoperative mean plasminogen activator activity and the
value on the fifth postoperative day. However, the mean plas-
minogen activator values immediately after and on the third
postoperative day were significantly lower and higher, respec-
tively (P , 0.001), than the preoperative and 5-day postoper-
ative mean plasminogen activator activity.
A different pattern of plasminogen activator values is seen
in Table 3 for the complicated cases. During the postoperative
period for the six complicated eyes, the mean plasminogen
activator value decreased to 23% of the preoperative mean
value immediately after the PRK treatment and remained at the
25% level through the third postoperative day. By the fifth day,
the mean plasminogen activator level was 16% above the pre-
operative mean value. The mean plasminogen activator values
immediately after PRK and on the third postoperative day were
not significantly different (P 5 0.81) from one another, and
each was significantly less (P , 0.001) than the preoperative
FIGURE 1. Plasminogen activator activities before and after PRK show-
ing the cluster of individual normal values compared with the cluster
of individual complicated cases.
FIGURE 2. Plasminogen activator activities in the contralateral eye
before and after PRK, showing the individual cases of contralateral-to-
normal eyes and contralateral-to-complicated eyes.
TABLE 1. Characteristics of Patients
Age (y) Contact Lenses (y)
Normal (n) 27 6 9 (40) 4 6 2 (15)
Complicated (n) 23 6 5 (5) 5 6 2 (4)
P 0.38 0.35
P (normal vs. complicated eyes) by Student’s t-test. Data are
means 6 SD.
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mean plasminogen activator value. In addition, there was a
significant increase (P 5 0.02) in mean plasminogen activator
activity on the fifth postoperative day compared with the
preoperative mean value.
The plasminogen activator mean values for the normal and
complicated cases are compared in Table 3. The preoperative
mean value is significantly lower (P 5 0.04) for the compli-
cated cases than the corresponding normal plasminogen acti-
vator mean value. However, the plasminogen activator mean
values immediately after PRK and 3 days after surgery for the
complicated eyes were not significantly different from the
immediate postoperative plasminogen activator mean value for
normal eyes (P . 0.14). On the third postoperative day, there
was a highly significant difference (P , 0.001) between the
plasminogen activator mean value for the complicated eyes
and that for the normal eyes.
The contralateral plasminogen activator mean levels are
shown in Table 3. The mean plasminogen activator activity
levels (normal group: 0.299 6 0.087 IU/ml; complicated
group: 0.192 6 0.026 IU/ml) remained steady (Fig. 2) over the
5-day measurement period (mean change in value, normal
group: 0.019 6 0.023 IU/ml; complicated group: 0.011 6
0.007 IU/ml). The mean plasminogen activator levels in the
contralateral complicated cases were significantly lower (P ,
0.001) than the corresponding mean levels of the contralateral
normal eyes. Levels in both contralateral groups differed sig-
nificantly from the PRK-treated eyes immediately after and 3
days after surgery.
DISCUSSION
The interesting observation in this study is that normal and
complicated corneal healing after PRK surgery were accompa-
nied by different patterns of plasminogen activator values and
specifically a significant difference on the third postoperative
day (Fig. 1). The low plasminogen activator values for the
complicated cases were sufficiently separated from the higher
normal group values on the third postoperative day that there
was some promise of distinguishability (Fig. 1). Therefore,
determination of plasminogen activator activity and compari-
sons with preoperative and normal values at the third postop-
erative day may serve predictive and diagnostic purposes in the
identification of patients who are prone to abnormal corneal
wound healing. Six of six retrospectively identified eyes
showed the effect, and all 71 remaining eyes showed no ensu-
ing haze: this corresponds to a sensitivity of 1.0 and a speci-
ficity of 1.0. If low (below 0.1 IU/ml) plasminogen activator
activity on postoperative day 3 were used to prospectively
identify (predict) eyes in which wound healing abnormalities
(haze) might develop, six of six eyes would have given a valid
prediction. Although six eyes were sufficient to provide statis-
tical meaning, additional complicated corneal healing cases
should be investigated to increase the statistical validity of the
results.22
When the contralateral control eye was measured, the tear
fluid flow and plasminogen activator activities remained essen-
tially constant (Fig. 2). This implies that PRK surgery and tear
sampling have little collateral effect on changes in tearing or
fibrinolytic activity in the contralateral eye. The preoperative
plasminogen activator mean values for the complicated and
corresponding contralateral eyes are significantly lower than
the mean plasminogen activator levels in the normal groups
(Table 3). This may indicate a predisposing factor for the
complicated eyes. Moreover, for each of the three patients in
the complicated group who had one normal and one compli-
cated eye, the preoperative plasminogen activator value was
lower in the eye that became complicated. However, the
ranges of plasminogen activator activity for the normal and
complicated groups overlapped on the preoperative measure-
ment (Figs. 1 and 2). Therefore, the normal and complicated
eyes were not distinguishable on the basis of the preoperative
plasminogen activator activity level.
A previous study investigated the tear fluid level of plas-
minogen activator activities and the plasmin level of seven
rabbits (11 eyes) during wound healing after anterior keratec-
tomy. In that study, plasmin and plasminogen activator activi-
ties were determined using radial caseinolysis procedures.18 A
pattern of plasminogen activator activity was found in the
rabbit after surgery that was qualitatively similar to the pattern
of plasminogen activator over time found here in Figure 1 for
TABLE 2. Visual and Surgical Characteristics
Pre-PRK
Astigmatism
(Cylinder)
Pre-PRK
Refraction
(D)
Ablation
Depth
(mm)
Normal (n) 21.6 6 0.6 (16) 22.9 6 3.1 (71) 47 6 22 (71)
Complicated (n) 21.0 6 0.0 (2) 25.1 6 1.3 (6) 57 6 23 (6)
P 0.24 0.08 0.33
P (normal vs. complicated eyes) by Student’s t-test. Data are
means 6 SD.
TABLE 3. Plasminogen Activator Activities
Pre-PRK
(IU/ml)
Post-PRK
(IU/ml)
Post-PRK 13
Days
Post-PRK 15
Days
Normal (n 5 71) 0.259 6 0.082 0.027 6 0.029 0.366 6 0.109 0.269 6 0.085
Complicated (n 5 6) 0.188 6 0.045 0.043 6 0.015 0.046 6 0.041 0.218 6 0.056
Contralateral Normal (n 5 16) 0.299 6 0.092 0.297 6 0.086 0.290 6 0.080 0.310 6 0.097
Contralateral Complicated (n 5 4) 0.195 6 0.033 0.192 6 0.024 0.191 6 0.032 0.190 6 0.027
P (normal versus complicated) 0.04 0.21 ,0.001 0.15
P (contralateral normal versus
normal) 0.74 ,0.001 0.002 0.87
P (contralateral complicated
versus complicated) 0.49 ,0.001 0.006 0.83
P by Student’s t-test. Data are means 6 SD.
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our normal cases. In particular, for 11 rabbit eyes, the mean
(6SEM) preoperative plasminogen activator activity in the rab-
bit was 2.0 6 0.6 IU/ml; this declined to 0.3 6 0.1 IU/ml after
surgery and then increased to 2.1 6 0.3 IU/ml during wound
healing.18 This agreement in the pattern of plasminogen acti-
vator values strengthens the notion that there is a normal
pattern leading to normal, healthy wound healing.
In the previous rabbit study,18 tear fluid flow was mea-
sured in addition to plasminogen activator activity. The tear
fluid flow was found to increase after anterior keratectomy by
a factor of 2.3 compared with preoperative flow. Therefore,
dilution of plasminogen activator was offered as a possible
explanation for the decrease in postoperative plasminogen
activator level.13 However, the plasminogen activator did not
change by the dilution factor of 2.3: The level of plasminogen
activator decreased after surgery by a factor of 6.7 compared
with preoperative levels.18 Therefore, dilution alone is not a
sufficient mechanism to explain the decrease in plasminogen
activator level. In the present work, the tear fluid flow re-
mained in the range of 5 to 15 ml/min for all eyes over all
sample times. Therefore, tear fluid flow levels cannot be re-
sponsible for the lowered plasminogen activator activities seen
after PRK in this work.
Although the exact mechanisms underlying post-PRK cor-
neal healing complications are unknown, it is generally sus-
pected that individual variations in corneal wound healing play
a significant role in post-PRK refractive regression and haze
formation.23 Low plasminogen activator activity sustained over
a period of 3 days, evidenced in tear fluid, is an accompanying
sign of the complicated PRK-treated eyes observed in this
study. It is not possible from the present results to distinguish
whether the low plasminogen activator activity is a primary
phenomenon or a result of some other primary event. How-
ever, based on its known importance in the wound healing
process, we conclude that prolonged low plasminogen activa-
tor activity could be a possible cause of defective corneal
healing. The determination of plasminogen activator activity
on postoperative day 3 could be a strong predictor to identify
patients who are vulnerable to future visual abnormalities
(haze). The concept of treatment intended to minimize degra-
dation and tissue removal due to the plasminogen activator–
plasmin system could open a new area of investigation for the
postoperative management of PRK.
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